Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy

John M. Abraham, Yulan Cheng, James Hamilton, Bogdan Paun, Zhe Jin, Rachana Agarwal, Takatsugu Kan, Stefan David, Alexandru Olaru, Jian Yang, Tetsuo Ito, Florin Selaru, Yuriko Mori, Stephen Meltzer

Research output: Contribution to journalArticle

Abstract

Cancers have been revealed to be extremely heterogenous in terms of the frequency and types of mutations present in cells from different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. We describe the generation of multiple, unique small peptides nine to thirty-four amino acids in length which, when labeled with the radioisotope 32P, bind with vastly differing efficiencies to cell lines derived from different colon adenocarcinomas. In addition, the most effective of these peptides permanently transfers the 32P radioisotope to colorectal cancer cellular proteins within two hours at a rate that is more than 150 times higher than in cell lines derived from other cancers or from the normal tissues tested. Currently, the only two FDA-approved radioimmunotherapeutic agents in use both employ antibodies directed against the B cell marker CD20 for the treatment of non-Hodgkin's lymphoma. By using the method described herein, large numbers of different 32P-labeled peptides can be readily produced and assayed against a broad spectrum of cancer types. This report proposes the development and use of 32P-labeled peptides as potential individualized peptide-binding therapies for the treatment of colon adenocarcinoma patients.

Original languageEnglish (US)
Article numbere2508
JournalPLoS One
Volume3
Issue number6
DOIs
StatePublished - Jun 25 2008

Fingerprint

colorectal neoplasms
Colorectal Neoplasms
peptides
therapeutics
Peptides
neoplasms
Cells
radionuclides
adenocarcinoma
Radioisotopes
colon
Neoplasms
Colon
Adenocarcinoma
cell lines
non-Hodgkin lymphoma
Therapeutics
Cell Line
Mutation Rate
Non-Hodgkin's Lymphoma

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy. / Abraham, John M.; Cheng, Yulan; Hamilton, James; Paun, Bogdan; Jin, Zhe; Agarwal, Rachana; Kan, Takatsugu; David, Stefan; Olaru, Alexandru; Yang, Jian; Ito, Tetsuo; Selaru, Florin; Mori, Yuriko; Meltzer, Stephen.

In: PLoS One, Vol. 3, No. 6, e2508, 25.06.2008.

Research output: Contribution to journalArticle

Abraham, JM, Cheng, Y, Hamilton, J, Paun, B, Jin, Z, Agarwal, R, Kan, T, David, S, Olaru, A, Yang, J, Ito, T, Selaru, F, Mori, Y & Meltzer, S 2008, 'Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy', PLoS One, vol. 3, no. 6, e2508. https://doi.org/10.1371/journal.pone.0002508
Abraham, John M. ; Cheng, Yulan ; Hamilton, James ; Paun, Bogdan ; Jin, Zhe ; Agarwal, Rachana ; Kan, Takatsugu ; David, Stefan ; Olaru, Alexandru ; Yang, Jian ; Ito, Tetsuo ; Selaru, Florin ; Mori, Yuriko ; Meltzer, Stephen. / Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy. In: PLoS One. 2008 ; Vol. 3, No. 6.
@article{c1863ee397604ec784a865015eb2d047,
title = "Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy",
abstract = "Cancers have been revealed to be extremely heterogenous in terms of the frequency and types of mutations present in cells from different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. We describe the generation of multiple, unique small peptides nine to thirty-four amino acids in length which, when labeled with the radioisotope 32P, bind with vastly differing efficiencies to cell lines derived from different colon adenocarcinomas. In addition, the most effective of these peptides permanently transfers the 32P radioisotope to colorectal cancer cellular proteins within two hours at a rate that is more than 150 times higher than in cell lines derived from other cancers or from the normal tissues tested. Currently, the only two FDA-approved radioimmunotherapeutic agents in use both employ antibodies directed against the B cell marker CD20 for the treatment of non-Hodgkin's lymphoma. By using the method described herein, large numbers of different 32P-labeled peptides can be readily produced and assayed against a broad spectrum of cancer types. This report proposes the development and use of 32P-labeled peptides as potential individualized peptide-binding therapies for the treatment of colon adenocarcinoma patients.",
author = "Abraham, {John M.} and Yulan Cheng and James Hamilton and Bogdan Paun and Zhe Jin and Rachana Agarwal and Takatsugu Kan and Stefan David and Alexandru Olaru and Jian Yang and Tetsuo Ito and Florin Selaru and Yuriko Mori and Stephen Meltzer",
year = "2008",
month = "6",
day = "25",
doi = "10.1371/journal.pone.0002508",
language = "English (US)",
volume = "3",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy

AU - Abraham, John M.

AU - Cheng, Yulan

AU - Hamilton, James

AU - Paun, Bogdan

AU - Jin, Zhe

AU - Agarwal, Rachana

AU - Kan, Takatsugu

AU - David, Stefan

AU - Olaru, Alexandru

AU - Yang, Jian

AU - Ito, Tetsuo

AU - Selaru, Florin

AU - Mori, Yuriko

AU - Meltzer, Stephen

PY - 2008/6/25

Y1 - 2008/6/25

N2 - Cancers have been revealed to be extremely heterogenous in terms of the frequency and types of mutations present in cells from different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. We describe the generation of multiple, unique small peptides nine to thirty-four amino acids in length which, when labeled with the radioisotope 32P, bind with vastly differing efficiencies to cell lines derived from different colon adenocarcinomas. In addition, the most effective of these peptides permanently transfers the 32P radioisotope to colorectal cancer cellular proteins within two hours at a rate that is more than 150 times higher than in cell lines derived from other cancers or from the normal tissues tested. Currently, the only two FDA-approved radioimmunotherapeutic agents in use both employ antibodies directed against the B cell marker CD20 for the treatment of non-Hodgkin's lymphoma. By using the method described herein, large numbers of different 32P-labeled peptides can be readily produced and assayed against a broad spectrum of cancer types. This report proposes the development and use of 32P-labeled peptides as potential individualized peptide-binding therapies for the treatment of colon adenocarcinoma patients.

AB - Cancers have been revealed to be extremely heterogenous in terms of the frequency and types of mutations present in cells from different malignant tumors. Thus, it is likely that uniform clinical treatment is not optimal for all patients, and that the development of individualized therapeutic regimens may be beneficial. We describe the generation of multiple, unique small peptides nine to thirty-four amino acids in length which, when labeled with the radioisotope 32P, bind with vastly differing efficiencies to cell lines derived from different colon adenocarcinomas. In addition, the most effective of these peptides permanently transfers the 32P radioisotope to colorectal cancer cellular proteins within two hours at a rate that is more than 150 times higher than in cell lines derived from other cancers or from the normal tissues tested. Currently, the only two FDA-approved radioimmunotherapeutic agents in use both employ antibodies directed against the B cell marker CD20 for the treatment of non-Hodgkin's lymphoma. By using the method described herein, large numbers of different 32P-labeled peptides can be readily produced and assayed against a broad spectrum of cancer types. This report proposes the development and use of 32P-labeled peptides as potential individualized peptide-binding therapies for the treatment of colon adenocarcinoma patients.

UR - http://www.scopus.com/inward/record.url?scp=49249104670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49249104670&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0002508

DO - 10.1371/journal.pone.0002508

M3 - Article

VL - 3

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e2508

ER -